Understanding the inter‐relationship between improved glycaemic control, hypoglycaemia and weight change within a long‐term economic model
- 30 March 2010
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 12 (5), 431-436
- https://doi.org/10.1111/j.1463-1326.2009.01184.x
Abstract
Background: Current guidelines for the management of type 2 diabetes advocate the attainment of sustained near normal glycaemia levels. Metformin is widely accepted as the treatment of choice for the initiation of pharmacotherapy; however, secondary failure of oral monotherapy occurs in 60% of patients resulting in the need for multiple pharmacotherapies. Therapy‐related consequences of treatment, such as weight gain and hypoglycaemia impact on the cost‐effectiveness profile of various agents. We therefore sought to ascertain the respective contribution of hypoglycaemia, weight change and improved blood glucose control on second‐line therapy options added to metformin. Methods: This study uses a simulation model designed to evaluate the cost utility of new therapies in a population of patients with type 2 diabetes mellitus. Standard model outputs include incidence of micro‐ and macrovascular complications and diabetes‐specific and all‐cause mortality. Results: The mean discounted quality‐adjusted life year (QALY) predicted by the model was 12.31 years. Reducing Glycosylated haemoglobin (HbA1c) by 1% gave a predicted gain of 0.413 QALYs per patient. A 3‐kg weight loss and 30% reduction in hypoglycaemia frequency produced a combined QALY gain of 0.355, whereas the reverse gave a QALY decrement of 0.356. Conclusions: The results of this analysis quantify the QALY decrement that may result from adverse therapy effects. The beneficial effects of improved glycaemic control on QALYs may be offset by characteristic treatment‐specific adverse effects, such as weight gain and hypoglycaemia frequency.This publication has 31 references indexed in Scilit:
- Trends in the prevalence and incidence of diabetes in the UK: 1996-2005Journal of Epidemiology and Community Health, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 DiabetesThe New England Journal of Medicine, 2008
- UKPDS—modelling of cardiovascular risk assessment and lifetime simulation of outcomesDiabetic Medicine, 2008
- Cost‐effectiveness of sitagliptin‐based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapyDiabetes, Obesity and Metabolism, 2008
- Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)Diabetologia, 2005
- Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)Medical Decision Making, 2002
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ, 1998
- UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six yearsDiabetic Medicine, 1998